CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Jazz Pharmaceuticals PLC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Jazz Pharmaceuticals PLC
Fifth Fl
Waterloo Exchange, Waterloo Road
Phone: +353 16347800p:+353 16347800 DUBLIN, 4  Ireland Ticker: JAZZJAZZ
Business Summary
Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).
(Source: 10KSB40)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-YesYesYes-

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer Bruce C.Cozadd 59 3/1/2020 1/1/2003
President, Chief Operating Officer Renee D.Gala 51 10/1/2023 3/16/2020
Chief Financial Officer, Executive Vice President PhilipJohnson 59 3/1/2024 3/1/2024
10 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Jazz Financing I Designated Activity Company Fift Floor Waterloo Exchange Ireland
GW Pharmaceuticals PLC Sovereign House Cambridge United Kingdom
GW Pharmaceuticals plc (OLD) Sovereign House CAMBRIDGE United Kingdom
13 additional Subsidiary records available in full report.

Business Names
Business Name
Azur Pharma Public Limited Company
Cavion Inc
Celator Pharmaceuticals Inc
26 additional Business Names available in full report.

General Information
Number of Employees: 2,800 (As of 12/31/2023)
Outstanding Shares: 62,345,283 (As of 2/21/2024)
Shareholders: 889
Stock Exchange: NASD
Federal Tax Id: 050563787
Fax Number: +353 16347850


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, April 28, 2024